Physician profile
Stefan Chin
NPI 1891794152
$13,846.23
in general payments reported to CMS, 2019-2025
34 companies · $1,944 in 2025
The $1,944 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,827 · 2020: $1,631 · 2021: $2,715 · 2022: $2,255 · 2023: $1,864 · 2024: $1,610 · 2025: $1,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,325 · Education: $92.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,325.36 |
| Education | $92.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,055.40 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,857.13 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $1,692.60 | 2019-2025 | |
| Janssen Biotech, INC. | $951.68 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $816.08 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ironwood Pharmaceuticals, INC | $662.44 | 2019-2025 | Linzess |
| Madrigal Pharmaceuticals | $582.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $377.03 | 2021-2023 | |
| Daiichi Sankyo INC. | $339.87 | 2019-2022 | |
| Allergan, INC. | $298.35 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $251.11 | 2024-2025 | Zenpep, Vowst |
| Ardelyx, INC. | $231.91 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $229.71 | 2019-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $228.88 | 2019-2024 | Ocaliva |
| Celltrion USA INC. | $220.42 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $202.01 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $159.60 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Ferring Pharmaceuticals INC. | $86.03 | 2019 | |
| Qol Medical, LLC | $79.09 | 2019-2023 | Sucraid |
| Mauna Kea Technologies, INC. | $64.92 | 2023 | |
| Lilly USA, LLC | $64.82 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $60.44 | 2024 | Voquezna |
| Celgene Corporation | $57.02 | 2021-2022 | |
| Shionogi INC | $50.81 | 2019 | |
| Pfizer INC. | $39.26 | 2019 | |
| Mallinckrodt Hospital Products INC. | $36.97 | 2023 | Acthar |
| Alnylam Pharmaceuticals INC. | $36.46 | 2025 | Givlaari |
| Alfasigma USA, INC. | $23.85 | 2021 | |
| Shire North American Group INC | $21.05 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $20.98 | 2024 | |
| Boston Scientific Corporation | $15.21 | 2021 | |
| Concordia Pharmaceuticals INC. | $12.29 | 2019 | |
| Napo Pharmaceuticals INC | $12.29 | 2019 | |
| Ambu INC. | $8.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.